INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - GLIBA, VRTU, PRCP, WPX, EIDX

NEW YORK, Nov. 12, 2020

GCI Liberty, Inc. (NASDAQ: GLIBA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Liberty Broadband Corporation. If you are a GCI Liberty shareholder, click on this link to learn more about your legal rights and options: https://halpersadeh.com/actions/gci-liberty-inc-gliba-stock-merger-liberty-broadband-technologies/.

Virtusa Corporation (NASDAQ: VRTU) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds affiliated with Baring Private Equity Asia for $51.35 per share. If you are a Virtusa shareholder, click on this link to learn more about your rights and options:  https://halpersadeh.com/actions/virtusa-corporation-vrtu-stock-merger-baring-asia/.

Perceptron, Inc. (NASDAQ: PRCP) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Atlas Copco for $7.00 per share. If you are a Perceptron shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/perceptron-inc-prcp-stock-merger-atlas-copco/.

WPX Energy, Inc. (NYSE: WPX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Devon Energy Corporation for 0.5165 shares of Devon common stock for each share of WPX common stock. If you are a WPX Energy shareholder, click on this link to learn more about your legal rights and options: https://halpersadeh.com/actions/wpx-energy-inc-stock-merger-devon/.

Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc.  Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. If you are an Eidos shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/eidos-therapeutics-inc-eidx-stock-merger-bridgebio/.